Cargando…

Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib

The sterile inflammatory response mediated by Toll-like receptors (TLRs) 4 and 9 is implicated in the massive hepatic damage caused by acetaminophen (APAP)-overdose. There is a crosstalk between TLR-dependent signaling with other intracellular kinases like phosphatidylinositol 3-kinases (PI3Ks). Nev...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaker, Mohamed E., Gomaa, Hesham A. M., Hazem, Sara H., Abdelgawad, Mohamed A., El-Mesery, Mohamed, Shaaban, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441125/
https://www.ncbi.nlm.nih.gov/pubmed/37608890
http://dx.doi.org/10.3389/fphar.2023.1212771
_version_ 1785093308232499200
author Shaker, Mohamed E.
Gomaa, Hesham A. M.
Hazem, Sara H.
Abdelgawad, Mohamed A.
El-Mesery, Mohamed
Shaaban, Ahmed A.
author_facet Shaker, Mohamed E.
Gomaa, Hesham A. M.
Hazem, Sara H.
Abdelgawad, Mohamed A.
El-Mesery, Mohamed
Shaaban, Ahmed A.
author_sort Shaker, Mohamed E.
collection PubMed
description The sterile inflammatory response mediated by Toll-like receptors (TLRs) 4 and 9 is implicated in the massive hepatic damage caused by acetaminophen (APAP)-overdose. There is a crosstalk between TLR-dependent signaling with other intracellular kinases like phosphatidylinositol 3-kinases (PI3Ks). Nevertheless, the detailed role of PI3Kα is still unknown in hepatic sterile inflammation. Accordingly, the effect of the novel PI3Kα inhibitor alpelisib was investigated in the setting of APAP-driven sterile inflammation in the liver. This was examined by pretreating mice with alpelisib (5 and 10 mg/kg, oral) 2 h before APAP (500 mg/kg, i.p.)-intoxication. The results indicated that alpelisib dose-dependently lowered APAP-induced escalation in serum liver function biomarkers and hepatic necroinflammation score. Alpelisib also attenuated APAP-induced rise in cleaved caspase 3 and proliferating cell nuclear antigen (PCNA) in the liver hepatocytes, as indices for apoptosis and proliferation. Mechanistically, inhibition of PI3Kα by alpelisib limited APAP-induced overproduction of the pro-inflammatory tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 in the blood circulation via switching off the activation of several signal transduction proteins, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), signal transducer and activator of transcription-3 (Stat-3), glycogen Synthase Kinase (GSK)-3β and nuclear factor (NF)-κB. Alpelisib also impaired APAP-instigated immune cell infiltration in the liver via reducing systemic granulocyte/macrophage-colony stimulating factor (GM-CSF) release and reversed APAP-induced abnormalities in the systemic and hepatic levels of the anti-inflammatory IL-10 and IL-22. In conclusion, selective modulation of the PI3Kα activity by alpelisib can hinder the inflammatory response and infiltration of immune cells occurring by APAP-hepatotoxicity.
format Online
Article
Text
id pubmed-10441125
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104411252023-08-22 Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib Shaker, Mohamed E. Gomaa, Hesham A. M. Hazem, Sara H. Abdelgawad, Mohamed A. El-Mesery, Mohamed Shaaban, Ahmed A. Front Pharmacol Pharmacology The sterile inflammatory response mediated by Toll-like receptors (TLRs) 4 and 9 is implicated in the massive hepatic damage caused by acetaminophen (APAP)-overdose. There is a crosstalk between TLR-dependent signaling with other intracellular kinases like phosphatidylinositol 3-kinases (PI3Ks). Nevertheless, the detailed role of PI3Kα is still unknown in hepatic sterile inflammation. Accordingly, the effect of the novel PI3Kα inhibitor alpelisib was investigated in the setting of APAP-driven sterile inflammation in the liver. This was examined by pretreating mice with alpelisib (5 and 10 mg/kg, oral) 2 h before APAP (500 mg/kg, i.p.)-intoxication. The results indicated that alpelisib dose-dependently lowered APAP-induced escalation in serum liver function biomarkers and hepatic necroinflammation score. Alpelisib also attenuated APAP-induced rise in cleaved caspase 3 and proliferating cell nuclear antigen (PCNA) in the liver hepatocytes, as indices for apoptosis and proliferation. Mechanistically, inhibition of PI3Kα by alpelisib limited APAP-induced overproduction of the pro-inflammatory tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 in the blood circulation via switching off the activation of several signal transduction proteins, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), signal transducer and activator of transcription-3 (Stat-3), glycogen Synthase Kinase (GSK)-3β and nuclear factor (NF)-κB. Alpelisib also impaired APAP-instigated immune cell infiltration in the liver via reducing systemic granulocyte/macrophage-colony stimulating factor (GM-CSF) release and reversed APAP-induced abnormalities in the systemic and hepatic levels of the anti-inflammatory IL-10 and IL-22. In conclusion, selective modulation of the PI3Kα activity by alpelisib can hinder the inflammatory response and infiltration of immune cells occurring by APAP-hepatotoxicity. Frontiers Media S.A. 2023-08-07 /pmc/articles/PMC10441125/ /pubmed/37608890 http://dx.doi.org/10.3389/fphar.2023.1212771 Text en Copyright © 2023 Shaker, Gomaa, Hazem, Abdelgawad, El-Mesery and Shaaban. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Shaker, Mohamed E.
Gomaa, Hesham A. M.
Hazem, Sara H.
Abdelgawad, Mohamed A.
El-Mesery, Mohamed
Shaaban, Ahmed A.
Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
title Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
title_full Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
title_fullStr Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
title_full_unstemmed Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
title_short Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
title_sort mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441125/
https://www.ncbi.nlm.nih.gov/pubmed/37608890
http://dx.doi.org/10.3389/fphar.2023.1212771
work_keys_str_mv AT shakermohamede mitigationofacetaminopheninducedlivertoxicitybythenovelphosphatidylinositol3kinaseinhibitoralpelisib
AT gomaaheshamam mitigationofacetaminopheninducedlivertoxicitybythenovelphosphatidylinositol3kinaseinhibitoralpelisib
AT hazemsarah mitigationofacetaminopheninducedlivertoxicitybythenovelphosphatidylinositol3kinaseinhibitoralpelisib
AT abdelgawadmohameda mitigationofacetaminopheninducedlivertoxicitybythenovelphosphatidylinositol3kinaseinhibitoralpelisib
AT elmeserymohamed mitigationofacetaminopheninducedlivertoxicitybythenovelphosphatidylinositol3kinaseinhibitoralpelisib
AT shaabanahmeda mitigationofacetaminopheninducedlivertoxicitybythenovelphosphatidylinositol3kinaseinhibitoralpelisib